nodes	percent_of_prediction	percent_of_DWPC	metapath
Salmeterol—Food allergy—Capecitabine—esophageal cancer	0.0698	0.111	CcSEcCtD
Salmeterol—Lower respiratory tract infection—Capecitabine—esophageal cancer	0.0147	0.0234	CcSEcCtD
Salmeterol—Bronchial hyperreactivity—Methotrexate—esophageal cancer	0.0143	0.0228	CcSEcCtD
Salmeterol—Chronic obstructive pulmonary disease—Methotrexate—esophageal cancer	0.0131	0.0208	CcSEcCtD
Salmeterol—Hoarseness—Capecitabine—esophageal cancer	0.0114	0.0182	CcSEcCtD
Salmeterol—Sneezing—Capecitabine—esophageal cancer	0.00907	0.0144	CcSEcCtD
Salmeterol—Rhinorrhoea—Cisplatin—esophageal cancer	0.00841	0.0134	CcSEcCtD
Salmeterol—Infection—Carboplatin—esophageal cancer	0.00824	0.0131	CcSEcCtD
Salmeterol—Oral candidiasis—Capecitabine—esophageal cancer	0.00791	0.0126	CcSEcCtD
Salmeterol—Tenderness—Cisplatin—esophageal cancer	0.00781	0.0124	CcSEcCtD
Salmeterol—Keratitis—Capecitabine—esophageal cancer	0.00775	0.0123	CcSEcCtD
Salmeterol—Supraventricular tachycardia—Capecitabine—esophageal cancer	0.00767	0.0122	CcSEcCtD
Salmeterol—Pain—Carboplatin—esophageal cancer	0.00709	0.0113	CcSEcCtD
Salmeterol—Throat sore—Capecitabine—esophageal cancer	0.00697	0.0111	CcSEcCtD
Salmeterol—Laryngitis—Capecitabine—esophageal cancer	0.00697	0.0111	CcSEcCtD
Salmeterol—Oropharyngeal discomfort—Capecitabine—esophageal cancer	0.00691	0.011	CcSEcCtD
Salmeterol—Body temperature increased—Carboplatin—esophageal cancer	0.00655	0.0104	CcSEcCtD
Salmeterol—Rhinorrhoea—Capecitabine—esophageal cancer	0.0062	0.00986	CcSEcCtD
Salmeterol—Dysphonia—Capecitabine—esophageal cancer	0.00611	0.00971	CcSEcCtD
Salmeterol—Extrasystoles—Capecitabine—esophageal cancer	0.00597	0.00949	CcSEcCtD
Salmeterol—Contusion—Capecitabine—esophageal cancer	0.00576	0.00916	CcSEcCtD
Salmeterol—Chest discomfort—Capecitabine—esophageal cancer	0.00568	0.00903	CcSEcCtD
Salmeterol—Musculoskeletal stiffness—Capecitabine—esophageal cancer	0.0056	0.00891	CcSEcCtD
Salmeterol—Oropharyngeal pain—Capecitabine—esophageal cancer	0.00552	0.00879	CcSEcCtD
Salmeterol—Nasal congestion—Cisplatin—esophageal cancer	0.00543	0.00864	CcSEcCtD
Salmeterol—Cataract—Capecitabine—esophageal cancer	0.00528	0.00839	CcSEcCtD
Salmeterol—Bone pain—Capecitabine—esophageal cancer	0.00524	0.00834	CcSEcCtD
Salmeterol—Inflammation—Capecitabine—esophageal cancer	0.00518	0.00824	CcSEcCtD
Salmeterol—Neck pain—Capecitabine—esophageal cancer	0.00508	0.00809	CcSEcCtD
Salmeterol—Candida infection—Capecitabine—esophageal cancer	0.0048	0.00763	CcSEcCtD
Salmeterol—Irritability—Cisplatin—esophageal cancer	0.00472	0.00751	CcSEcCtD
Salmeterol—Cramp muscle—Cisplatin—esophageal cancer	0.00445	0.00708	CcSEcCtD
Salmeterol—Nasopharyngitis—Cisplatin—esophageal cancer	0.00442	0.00704	CcSEcCtD
Salmeterol—Ear pain—Capecitabine—esophageal cancer	0.00427	0.0068	CcSEcCtD
Salmeterol—Sleep disorder—Capecitabine—esophageal cancer	0.00421	0.0067	CcSEcCtD
Salmeterol—Musculoskeletal stiffness—Methotrexate—esophageal cancer	0.00417	0.00663	CcSEcCtD
Salmeterol—Swelling—Capecitabine—esophageal cancer	0.00413	0.00657	CcSEcCtD
Salmeterol—Gastroenteritis—Capecitabine—esophageal cancer	0.00411	0.00654	CcSEcCtD
Salmeterol—Abdominal discomfort—Cisplatin—esophageal cancer	0.0041	0.00652	CcSEcCtD
Salmeterol—Inflammation—Methotrexate—esophageal cancer	0.00386	0.00613	CcSEcCtD
Salmeterol—Atrial fibrillation—Capecitabine—esophageal cancer	0.00385	0.00612	CcSEcCtD
Salmeterol—Conjunctivitis—Cisplatin—esophageal cancer	0.00371	0.00589	CcSEcCtD
Salmeterol—Pain in extremity—Capecitabine—esophageal cancer	0.00365	0.0058	CcSEcCtD
Salmeterol—Migraine—Capecitabine—esophageal cancer	0.00359	0.00571	CcSEcCtD
Salmeterol—Irritability—Capecitabine—esophageal cancer	0.00348	0.00554	CcSEcCtD
Salmeterol—Connective tissue disorder—Cisplatin—esophageal cancer	0.00336	0.00535	CcSEcCtD
Salmeterol—Abdominal pain upper—Capecitabine—esophageal cancer	0.00333	0.0053	CcSEcCtD
Salmeterol—Nasopharyngitis—Capecitabine—esophageal cancer	0.00326	0.00519	CcSEcCtD
Salmeterol—Cardiac disorder—Cisplatin—esophageal cancer	0.00318	0.00505	CcSEcCtD
Salmeterol—Influenza—Capecitabine—esophageal cancer	0.00315	0.00501	CcSEcCtD
Salmeterol—Asthma—Capecitabine—esophageal cancer	0.00315	0.00501	CcSEcCtD
Salmeterol—Bronchospasm—Capecitabine—esophageal cancer	0.0031	0.00493	CcSEcCtD
Salmeterol—Immune system disorder—Cisplatin—esophageal cancer	0.00309	0.00492	CcSEcCtD
Salmeterol—Mediastinal disorder—Cisplatin—esophageal cancer	0.00308	0.00491	CcSEcCtD
Salmeterol—Arrhythmia—Cisplatin—esophageal cancer	0.00306	0.00486	CcSEcCtD
Salmeterol—Bronchitis—Capecitabine—esophageal cancer	0.00303	0.00482	CcSEcCtD
Salmeterol—Abdominal discomfort—Capecitabine—esophageal cancer	0.00302	0.00481	CcSEcCtD
Salmeterol—Malnutrition—Cisplatin—esophageal cancer	0.00298	0.00474	CcSEcCtD
Salmeterol—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.00293	0.00466	CcSEcCtD
Salmeterol—Muscle spasms—Cisplatin—esophageal cancer	0.00286	0.00456	CcSEcCtD
Salmeterol—Hyperglycaemia—Capecitabine—esophageal cancer	0.00284	0.00452	CcSEcCtD
Salmeterol—Pneumonia—Capecitabine—esophageal cancer	0.00283	0.0045	CcSEcCtD
Salmeterol—Infestation NOS—Capecitabine—esophageal cancer	0.00281	0.00447	CcSEcCtD
Salmeterol—Infestation—Capecitabine—esophageal cancer	0.00281	0.00447	CcSEcCtD
Salmeterol—Tremor—Cisplatin—esophageal cancer	0.00279	0.00444	CcSEcCtD
Salmeterol—Ill-defined disorder—Cisplatin—esophageal cancer	0.00276	0.0044	CcSEcCtD
Salmeterol—Conjunctivitis—Capecitabine—esophageal cancer	0.00273	0.00434	CcSEcCtD
Salmeterol—Urinary tract infection—Capecitabine—esophageal cancer	0.00273	0.00434	CcSEcCtD
Salmeterol—Malaise—Cisplatin—esophageal cancer	0.00269	0.00427	CcSEcCtD
Salmeterol—Epistaxis—Capecitabine—esophageal cancer	0.00265	0.00422	CcSEcCtD
Salmeterol—Irritability—Methotrexate—esophageal cancer	0.00259	0.00412	CcSEcCtD
Salmeterol—Myalgia—Cisplatin—esophageal cancer	0.00254	0.00403	CcSEcCtD
Salmeterol—Rhinitis—Capecitabine—esophageal cancer	0.00253	0.00402	CcSEcCtD
Salmeterol—Anxiety—Cisplatin—esophageal cancer	0.00253	0.00402	CcSEcCtD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00252	0.00401	CcSEcCtD
Salmeterol—Discomfort—Cisplatin—esophageal cancer	0.00251	0.00399	CcSEcCtD
Salmeterol—Pharyngitis—Capecitabine—esophageal cancer	0.0025	0.00398	CcSEcCtD
Salmeterol—Connective tissue disorder—Capecitabine—esophageal cancer	0.00248	0.00394	CcSEcCtD
Salmeterol—Oedema—Cisplatin—esophageal cancer	0.00243	0.00387	CcSEcCtD
Salmeterol—Anaphylactic shock—Cisplatin—esophageal cancer	0.00243	0.00387	CcSEcCtD
Salmeterol—Infection—Cisplatin—esophageal cancer	0.00242	0.00384	CcSEcCtD
Salmeterol—Nervous system disorder—Cisplatin—esophageal cancer	0.00238	0.00379	CcSEcCtD
Salmeterol—Tachycardia—Cisplatin—esophageal cancer	0.00237	0.00377	CcSEcCtD
Salmeterol—Skin disorder—Cisplatin—esophageal cancer	0.00236	0.00376	CcSEcCtD
Salmeterol—Asthma—Methotrexate—esophageal cancer	0.00235	0.00373	CcSEcCtD
Salmeterol—Cardiac disorder—Capecitabine—esophageal cancer	0.00234	0.00372	CcSEcCtD
Salmeterol—Immune system disorder—Capecitabine—esophageal cancer	0.00228	0.00362	CcSEcCtD
Salmeterol—Mediastinal disorder—Capecitabine—esophageal cancer	0.00227	0.00362	CcSEcCtD
Salmeterol—Arrhythmia—Capecitabine—esophageal cancer	0.00225	0.00358	CcSEcCtD
Salmeterol—Abdominal discomfort—Methotrexate—esophageal cancer	0.00225	0.00358	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00222	0.00352	CcSEcCtD
Salmeterol—Mental disorder—Capecitabine—esophageal cancer	0.00221	0.00351	CcSEcCtD
Salmeterol—Malnutrition—Capecitabine—esophageal cancer	0.0022	0.00349	CcSEcCtD
Salmeterol—Paraesthesia—Cisplatin—esophageal cancer	0.00218	0.00347	CcSEcCtD
Salmeterol—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.00218	0.00347	CcSEcCtD
Salmeterol—Dyspnoea—Cisplatin—esophageal cancer	0.00217	0.00345	CcSEcCtD
Salmeterol—Back pain—Capecitabine—esophageal cancer	0.00212	0.00338	CcSEcCtD
Salmeterol—Muscle spasms—Capecitabine—esophageal cancer	0.00211	0.00336	CcSEcCtD
Salmeterol—Pneumonia—Methotrexate—esophageal cancer	0.0021	0.00335	CcSEcCtD
Salmeterol—Infestation NOS—Methotrexate—esophageal cancer	0.00209	0.00333	CcSEcCtD
Salmeterol—Infestation—Methotrexate—esophageal cancer	0.00209	0.00333	CcSEcCtD
Salmeterol—Pain—Cisplatin—esophageal cancer	0.00208	0.00331	CcSEcCtD
Salmeterol—Tremor—Capecitabine—esophageal cancer	0.00206	0.00327	CcSEcCtD
Salmeterol—Ill-defined disorder—Capecitabine—esophageal cancer	0.00204	0.00324	CcSEcCtD
Salmeterol—Conjunctivitis—Methotrexate—esophageal cancer	0.00203	0.00323	CcSEcCtD
Salmeterol—Feeling abnormal—Cisplatin—esophageal cancer	0.002	0.00319	CcSEcCtD
Salmeterol—Malaise—Capecitabine—esophageal cancer	0.00198	0.00315	CcSEcCtD
Salmeterol—Epistaxis—Methotrexate—esophageal cancer	0.00197	0.00314	CcSEcCtD
Salmeterol—Palpitations—Capecitabine—esophageal cancer	0.00194	0.00309	CcSEcCtD
Salmeterol—Body temperature increased—Cisplatin—esophageal cancer	0.00192	0.00306	CcSEcCtD
Salmeterol—Cough—Capecitabine—esophageal cancer	0.00192	0.00305	CcSEcCtD
Salmeterol—Hypertension—Capecitabine—esophageal cancer	0.0019	0.00302	CcSEcCtD
Salmeterol—Arthralgia—Capecitabine—esophageal cancer	0.00187	0.00297	CcSEcCtD
Salmeterol—Myalgia—Capecitabine—esophageal cancer	0.00187	0.00297	CcSEcCtD
Salmeterol—Chest pain—Capecitabine—esophageal cancer	0.00187	0.00297	CcSEcCtD
Salmeterol—Pharyngitis—Methotrexate—esophageal cancer	0.00186	0.00296	CcSEcCtD
Salmeterol—Anxiety—Capecitabine—esophageal cancer	0.00186	0.00296	CcSEcCtD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00186	0.00295	CcSEcCtD
Salmeterol—Discomfort—Capecitabine—esophageal cancer	0.00185	0.00294	CcSEcCtD
Salmeterol—Dry mouth—Capecitabine—esophageal cancer	0.00183	0.00291	CcSEcCtD
Salmeterol—Oedema—Capecitabine—esophageal cancer	0.00179	0.00285	CcSEcCtD
Salmeterol—Hypersensitivity—Cisplatin—esophageal cancer	0.00179	0.00285	CcSEcCtD
Salmeterol—Infection—Capecitabine—esophageal cancer	0.00178	0.00283	CcSEcCtD
Salmeterol—Nervous system disorder—Capecitabine—esophageal cancer	0.00176	0.0028	CcSEcCtD
Salmeterol—Tachycardia—Capecitabine—esophageal cancer	0.00175	0.00278	CcSEcCtD
Salmeterol—Asthenia—Cisplatin—esophageal cancer	0.00174	0.00277	CcSEcCtD
Salmeterol—Cardiac disorder—Methotrexate—esophageal cancer	0.00174	0.00277	CcSEcCtD
Salmeterol—Skin disorder—Capecitabine—esophageal cancer	0.00174	0.00277	CcSEcCtD
Salmeterol—Immune system disorder—Methotrexate—esophageal cancer	0.0017	0.0027	CcSEcCtD
Salmeterol—Mediastinal disorder—Methotrexate—esophageal cancer	0.00169	0.00269	CcSEcCtD
Salmeterol—Diarrhoea—Cisplatin—esophageal cancer	0.00166	0.00265	CcSEcCtD
Salmeterol—Mental disorder—Methotrexate—esophageal cancer	0.00165	0.00262	CcSEcCtD
Salmeterol—Malnutrition—Methotrexate—esophageal cancer	0.00163	0.0026	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00163	0.0026	CcSEcCtD
Salmeterol—Insomnia—Capecitabine—esophageal cancer	0.00162	0.00258	CcSEcCtD
Salmeterol—Paraesthesia—Capecitabine—esophageal cancer	0.00161	0.00256	CcSEcCtD
Salmeterol—Dyspnoea—Capecitabine—esophageal cancer	0.0016	0.00254	CcSEcCtD
Salmeterol—Back pain—Methotrexate—esophageal cancer	0.00158	0.00251	CcSEcCtD
Salmeterol—Dyspepsia—Capecitabine—esophageal cancer	0.00158	0.00251	CcSEcCtD
Salmeterol—Vomiting—Cisplatin—esophageal cancer	0.00155	0.00246	CcSEcCtD
Salmeterol—Fatigue—Capecitabine—esophageal cancer	0.00155	0.00246	CcSEcCtD
Salmeterol—Rash—Cisplatin—esophageal cancer	0.00153	0.00244	CcSEcCtD
Salmeterol—Pain—Capecitabine—esophageal cancer	0.00153	0.00244	CcSEcCtD
Salmeterol—Constipation—Capecitabine—esophageal cancer	0.00153	0.00244	CcSEcCtD
Salmeterol—Dermatitis—Cisplatin—esophageal cancer	0.00153	0.00244	CcSEcCtD
Salmeterol—Ill-defined disorder—Methotrexate—esophageal cancer	0.00152	0.00241	CcSEcCtD
Salmeterol—Feeling abnormal—Capecitabine—esophageal cancer	0.00148	0.00235	CcSEcCtD
Salmeterol—Malaise—Methotrexate—esophageal cancer	0.00147	0.00234	CcSEcCtD
Salmeterol—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00147	0.00233	CcSEcCtD
Salmeterol—Nausea—Cisplatin—esophageal cancer	0.00144	0.0023	CcSEcCtD
Salmeterol—Cough—Methotrexate—esophageal cancer	0.00143	0.00227	CcSEcCtD
Salmeterol—Urticaria—Capecitabine—esophageal cancer	0.00142	0.00226	CcSEcCtD
Salmeterol—Body temperature increased—Capecitabine—esophageal cancer	0.00142	0.00225	CcSEcCtD
Salmeterol—Abdominal pain—Capecitabine—esophageal cancer	0.00142	0.00225	CcSEcCtD
Salmeterol—Myalgia—Methotrexate—esophageal cancer	0.00139	0.00221	CcSEcCtD
Salmeterol—Chest pain—Methotrexate—esophageal cancer	0.00139	0.00221	CcSEcCtD
Salmeterol—Arthralgia—Methotrexate—esophageal cancer	0.00139	0.00221	CcSEcCtD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00138	0.0022	CcSEcCtD
Salmeterol—Discomfort—Methotrexate—esophageal cancer	0.00138	0.00219	CcSEcCtD
Salmeterol—Anaphylactic shock—Methotrexate—esophageal cancer	0.00133	0.00212	CcSEcCtD
Salmeterol—Infection—Methotrexate—esophageal cancer	0.00133	0.00211	CcSEcCtD
Salmeterol—Hypersensitivity—Capecitabine—esophageal cancer	0.00132	0.0021	CcSEcCtD
Salmeterol—Nervous system disorder—Methotrexate—esophageal cancer	0.00131	0.00208	CcSEcCtD
Salmeterol—Skin disorder—Methotrexate—esophageal cancer	0.0013	0.00206	CcSEcCtD
Salmeterol—Asthenia—Capecitabine—esophageal cancer	0.00129	0.00205	CcSEcCtD
Salmeterol—Diarrhoea—Capecitabine—esophageal cancer	0.00123	0.00195	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.00122	0.00193	CcSEcCtD
Salmeterol—Insomnia—Methotrexate—esophageal cancer	0.00121	0.00192	CcSEcCtD
Salmeterol—Paraesthesia—Methotrexate—esophageal cancer	0.0012	0.00191	CcSEcCtD
Salmeterol—Dyspnoea—Methotrexate—esophageal cancer	0.00119	0.00189	CcSEcCtD
Salmeterol—Dizziness—Capecitabine—esophageal cancer	0.00119	0.00188	CcSEcCtD
Salmeterol—Dyspepsia—Methotrexate—esophageal cancer	0.00117	0.00187	CcSEcCtD
Salmeterol—Fatigue—Methotrexate—esophageal cancer	0.00115	0.00183	CcSEcCtD
Salmeterol—Pain—Methotrexate—esophageal cancer	0.00114	0.00181	CcSEcCtD
Salmeterol—Vomiting—Capecitabine—esophageal cancer	0.00114	0.00181	CcSEcCtD
Salmeterol—Rash—Capecitabine—esophageal cancer	0.00113	0.0018	CcSEcCtD
Salmeterol—Dermatitis—Capecitabine—esophageal cancer	0.00113	0.0018	CcSEcCtD
Salmeterol—Headache—Capecitabine—esophageal cancer	0.00112	0.00179	CcSEcCtD
Salmeterol—Feeling abnormal—Methotrexate—esophageal cancer	0.0011	0.00175	CcSEcCtD
Salmeterol—Gastrointestinal pain—Methotrexate—esophageal cancer	0.00109	0.00174	CcSEcCtD
Salmeterol—Nausea—Capecitabine—esophageal cancer	0.00106	0.00169	CcSEcCtD
Salmeterol—Urticaria—Methotrexate—esophageal cancer	0.00106	0.00169	CcSEcCtD
Salmeterol—Abdominal pain—Methotrexate—esophageal cancer	0.00105	0.00168	CcSEcCtD
Salmeterol—Body temperature increased—Methotrexate—esophageal cancer	0.00105	0.00168	CcSEcCtD
Salmeterol—Hypersensitivity—Methotrexate—esophageal cancer	0.000983	0.00156	CcSEcCtD
Salmeterol—Asthenia—Methotrexate—esophageal cancer	0.000957	0.00152	CcSEcCtD
Salmeterol—Diarrhoea—Methotrexate—esophageal cancer	0.000913	0.00145	CcSEcCtD
Salmeterol—CYP3A7—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000889	0.0024	CbGpPWpGaD
Salmeterol—Dizziness—Methotrexate—esophageal cancer	0.000882	0.0014	CcSEcCtD
Salmeterol—CYP3A4—Tryptophan metabolism—CYP19A1—esophageal cancer	0.00087	0.00234	CbGpPWpGaD
Salmeterol—CYP3A5—Biological oxidations—GSTT1—esophageal cancer	0.00087	0.00234	CbGpPWpGaD
Salmeterol—CYP3A5—Biological oxidations—CYP2A6—esophageal cancer	0.00086	0.00232	CbGpPWpGaD
Salmeterol—Vomiting—Methotrexate—esophageal cancer	0.000848	0.00135	CcSEcCtD
Salmeterol—Rash—Methotrexate—esophageal cancer	0.000841	0.00134	CcSEcCtD
Salmeterol—Dermatitis—Methotrexate—esophageal cancer	0.000841	0.00134	CcSEcCtD
Salmeterol—Headache—Methotrexate—esophageal cancer	0.000836	0.00133	CcSEcCtD
Salmeterol—CYP3A5—Biological oxidations—PTGS1—esophageal cancer	0.000815	0.0022	CbGpPWpGaD
Salmeterol—CYP3A4—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.0008	0.00216	CbGpPWpGaD
Salmeterol—Nausea—Methotrexate—esophageal cancer	0.000793	0.00126	CcSEcCtD
Salmeterol—CYP2C8—Biological oxidations—ALDH2—esophageal cancer	0.000792	0.00213	CbGpPWpGaD
Salmeterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL2—esophageal cancer	0.000756	0.00204	CbGpPWpGaD
Salmeterol—CYP2C8—Biological oxidations—GSTT1—esophageal cancer	0.000753	0.00203	CbGpPWpGaD
Salmeterol—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000752	0.00203	CbGpPWpGaD
Salmeterol—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000748	0.00202	CbGpPWpGaD
Salmeterol—CYP2C8—Biological oxidations—CYP2A6—esophageal cancer	0.000745	0.00201	CbGpPWpGaD
Salmeterol—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000738	0.00199	CbGpPWpGaD
Salmeterol—CYP2C8—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.000727	0.00196	CbGpPWpGaD
Salmeterol—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000713	0.00192	CbGpPWpGaD
Salmeterol—CYP2C8—Biological oxidations—PTGS1—esophageal cancer	0.000706	0.0019	CbGpPWpGaD
Salmeterol—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000703	0.0019	CbGpPWpGaD
Salmeterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—ANXA1—esophageal cancer	0.000703	0.00189	CbGpPWpGaD
Salmeterol—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000694	0.00187	CbGpPWpGaD
Salmeterol—CYP3A5—Biological oxidations—CYP1B1—esophageal cancer	0.000693	0.00187	CbGpPWpGaD
Salmeterol—CYP3A4—Biological oxidations—ADH7—esophageal cancer	0.000688	0.00185	CbGpPWpGaD
Salmeterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—SST—esophageal cancer	0.000684	0.00184	CbGpPWpGaD
Salmeterol—CYP3A5—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000684	0.00184	CbGpPWpGaD
Salmeterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—GHRL—esophageal cancer	0.000666	0.0018	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.000659	0.00178	CbGpPWpGaD
Salmeterol—ADRB2—GPCR ligand binding—GNG7—esophageal cancer	0.000654	0.00176	CbGpPWpGaD
Salmeterol—CYP3A5—Biological oxidations—CYP19A1—esophageal cancer	0.000652	0.00176	CbGpPWpGaD
Salmeterol—CYP3A5—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000643	0.00173	CbGpPWpGaD
Salmeterol—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000607	0.00163	CbGpPWpGaD
Salmeterol—CYP3A4—Biological oxidations—ADH1B—esophageal cancer	0.000603	0.00163	CbGpPWpGaD
Salmeterol—CYP2C8—Biological oxidations—CYP1B1—esophageal cancer	0.0006	0.00162	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—ADCYAP1—esophageal cancer	0.000598	0.00161	CbGpPWpGaD
Salmeterol—CYP2C8—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000592	0.00159	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000579	0.00156	CbGpPWpGaD
Salmeterol—ADRB2—GPCR ligand binding—CXCL2—esophageal cancer	0.000576	0.00155	CbGpPWpGaD
Salmeterol—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.00057	0.00154	CbGpPWpGaD
Salmeterol—CYP2C8—Biological oxidations—CYP19A1—esophageal cancer	0.000564	0.00152	CbGpPWpGaD
Salmeterol—CYP3A4—Biological oxidations—CYP26A1—esophageal cancer	0.000561	0.00151	CbGpPWpGaD
Salmeterol—CYP2C8—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000557	0.0015	CbGpPWpGaD
Salmeterol—CYP3A4—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000553	0.00149	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—GDI2—esophageal cancer	0.000549	0.00148	CbGpPWpGaD
Salmeterol—ADRB2—GPCR ligand binding—ANXA1—esophageal cancer	0.000535	0.00144	CbGpPWpGaD
Salmeterol—CYP3A4—Biological oxidations—GSTO1—esophageal cancer	0.000522	0.00141	CbGpPWpGaD
Salmeterol—ADRB2—GPCR ligand binding—SST—esophageal cancer	0.000521	0.0014	CbGpPWpGaD
Salmeterol—CYP3A4—Metapathway biotransformation—GSTO1—esophageal cancer	0.000514	0.00139	CbGpPWpGaD
Salmeterol—ADRB2—GPCR ligand binding—GHRL—esophageal cancer	0.000507	0.00137	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—SLC52A3—esophageal cancer	0.000484	0.0013	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—BLVRB—esophageal cancer	0.000484	0.0013	CbGpPWpGaD
Salmeterol—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	0.000425	0.00115	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—AKAP13—esophageal cancer	0.000425	0.00114	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—SLC10A2—esophageal cancer	0.000412	0.00111	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CA1—esophageal cancer	0.000412	0.00111	CbGpPWpGaD
Salmeterol—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	0.000404	0.00109	CbGpPWpGaD
Salmeterol—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	0.0004	0.00108	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—KMT2D—esophageal cancer	0.000397	0.00107	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000391	0.00105	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—PDE4D—esophageal cancer	0.000388	0.00105	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—AKAP13—esophageal cancer	0.000386	0.00104	CbGpPWpGaD
Salmeterol—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	0.000379	0.00102	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CA2—esophageal cancer	0.000377	0.00101	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—GNG7—esophageal cancer	0.000369	0.000995	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—ADCYAP1—esophageal cancer	0.000353	0.000952	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—PDE4D—esophageal cancer	0.000353	0.00095	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—ADH7—esophageal cancer	0.00035	0.000943	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PLCE1—esophageal cancer	0.00035	0.000943	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—SLC52A3—esophageal cancer	0.00035	0.000943	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—BLVRB—esophageal cancer	0.00035	0.000943	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000341	0.000919	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—GNG7—esophageal cancer	0.000335	0.000904	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—CXCL2—esophageal cancer	0.000325	0.000877	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—WWOX—esophageal cancer	0.000323	0.000871	CbGpPWpGaD
Salmeterol—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	0.000322	0.000868	CbGpPWpGaD
Salmeterol—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000318	0.000856	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—FKBP1A—esophageal cancer	0.000307	0.000828	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—ADH1B—esophageal cancer	0.000307	0.000827	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—BLVRB—esophageal cancer	0.000303	0.000817	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—SLC52A3—esophageal cancer	0.000303	0.000817	CbGpPWpGaD
Salmeterol—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	0.000303	0.000816	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—ANXA1—esophageal cancer	0.000303	0.000815	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—WIF1—esophageal cancer	0.000301	0.00081	CbGpPWpGaD
Salmeterol—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000299	0.000805	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—SLC10A2—esophageal cancer	0.000298	0.000802	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CA1—esophageal cancer	0.000298	0.000802	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—CXCL2—esophageal cancer	0.000296	0.000796	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—SST—esophageal cancer	0.000294	0.000793	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—TYMP—esophageal cancer	0.000293	0.000791	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—GHRL—esophageal cancer	0.000287	0.000773	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CYP26A1—esophageal cancer	0.000285	0.000769	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—ALOX15—esophageal cancer	0.000278	0.000749	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CSNK1A1—esophageal cancer	0.000277	0.000747	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—ANXA1—esophageal cancer	0.000275	0.00074	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CA2—esophageal cancer	0.000272	0.000734	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000271	0.00073	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—SST—esophageal cancer	0.000267	0.00072	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—TPI1—esophageal cancer	0.000265	0.000715	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—GSTO1—esophageal cancer	0.000265	0.000715	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—GHRL—esophageal cancer	0.00026	0.000702	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PFN1—esophageal cancer	0.000259	0.000699	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CA1—esophageal cancer	0.000258	0.000695	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—SLC10A2—esophageal cancer	0.000258	0.000695	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—ALDOB—esophageal cancer	0.000254	0.000685	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PLCE1—esophageal cancer	0.000253	0.000682	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ADH7—esophageal cancer	0.000253	0.000682	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—GAPDH—esophageal cancer	0.000245	0.00066	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CRABP1—esophageal cancer	0.000243	0.000654	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CA2—esophageal cancer	0.000236	0.000635	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—ELMO1—esophageal cancer	0.000233	0.000628	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—GNG7—esophageal cancer	0.000231	0.000622	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000231	0.000621	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—AKAP13—esophageal cancer	0.000228	0.000614	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ADH1B—esophageal cancer	0.000222	0.000598	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PLCE1—esophageal cancer	0.000219	0.000591	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ADH7—esophageal cancer	0.000219	0.000591	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.000217	0.000584	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—ALDH2—esophageal cancer	0.000216	0.000583	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—TYMP—esophageal cancer	0.000212	0.000571	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—HIST1H2BM—esophageal cancer	0.00021	0.000566	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PDE4D—esophageal cancer	0.000208	0.000561	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CYP26A1—esophageal cancer	0.000206	0.000556	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—GSTT1—esophageal cancer	0.000206	0.000554	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CYP2A6—esophageal cancer	0.000203	0.000548	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ALOX15—esophageal cancer	0.000201	0.000542	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—GNG7—esophageal cancer	0.000198	0.000534	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—ENO1—esophageal cancer	0.000193	0.00052	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PTGS1—esophageal cancer	0.000193	0.00052	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ADH1B—esophageal cancer	0.000192	0.000518	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—TPI1—esophageal cancer	0.000192	0.000517	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—GSTO1—esophageal cancer	0.000192	0.000517	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PSME2—esophageal cancer	0.00019	0.000512	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PSME1—esophageal cancer	0.00019	0.000512	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—XIAP—esophageal cancer	0.000186	0.0005	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ALDOB—esophageal cancer	0.000184	0.000496	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—TYMP—esophageal cancer	0.000184	0.000495	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CYP26A1—esophageal cancer	0.000179	0.000482	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—GAPDH—esophageal cancer	0.000177	0.000477	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CTNNA1—esophageal cancer	0.000176	0.000473	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CRABP1—esophageal cancer	0.000175	0.000473	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CXCL2—esophageal cancer	0.000175	0.00047	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ALOX15—esophageal cancer	0.000174	0.000469	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—GNG7—esophageal cancer	0.000167	0.00045	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—TPI1—esophageal cancer	0.000166	0.000448	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GSTO1—esophageal cancer	0.000166	0.000448	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CYP1B1—esophageal cancer	0.000164	0.000442	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PSME1—esophageal cancer	0.000163	0.000439	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PSME2—esophageal cancer	0.000163	0.000439	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—BLVRB—esophageal cancer	0.000163	0.000439	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—SLC52A3—esophageal cancer	0.000163	0.000439	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—ANXA1—esophageal cancer	0.000162	0.000437	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ALDOB—esophageal cancer	0.000159	0.000429	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—SST—esophageal cancer	0.000158	0.000425	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ALDH2—esophageal cancer	0.000156	0.000421	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CYP19A1—esophageal cancer	0.000154	0.000415	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—NOTCH3—esophageal cancer	0.000154	0.000415	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—GHRL—esophageal cancer	0.000154	0.000415	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GAPDH—esophageal cancer	0.000153	0.000413	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CRABP1—esophageal cancer	0.000152	0.000409	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—FBXW7—esophageal cancer	0.000151	0.000408	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—GSTT1—esophageal cancer	0.000149	0.000401	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CYP2A6—esophageal cancer	0.000147	0.000396	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GNG7—esophageal cancer	0.000145	0.000389	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—HMOX1—esophageal cancer	0.000141	0.000379	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PTGS1—esophageal cancer	0.000139	0.000376	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ENO1—esophageal cancer	0.000139	0.000376	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CA1—esophageal cancer	0.000138	0.000373	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—SLC10A2—esophageal cancer	0.000138	0.000373	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—NOTCH2—esophageal cancer	0.000138	0.000372	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PSME2—esophageal cancer	0.000137	0.00037	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PSME1—esophageal cancer	0.000137	0.00037	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ALDH2—esophageal cancer	0.000135	0.000365	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—ABCB1—esophageal cancer	0.000135	0.000364	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GSTT1—esophageal cancer	0.000129	0.000347	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CYP2A6—esophageal cancer	0.000127	0.000343	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	0.000127	0.000342	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CA2—esophageal cancer	0.000127	0.000341	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—TGFBR2—esophageal cancer	0.000122	0.00033	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ENO1—esophageal cancer	0.000121	0.000325	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PTGS1—esophageal cancer	0.000121	0.000325	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PSME2—esophageal cancer	0.000119	0.000321	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PSME1—esophageal cancer	0.000119	0.000321	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CYP1B1—esophageal cancer	0.000119	0.000319	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PLCE1—esophageal cancer	0.000118	0.000317	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ADH7—esophageal cancer	0.000118	0.000317	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—SMAD4—esophageal cancer	0.000116	0.000312	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CYP19A1—esophageal cancer	0.000111	0.0003	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	0.000104	0.00028	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ADH1B—esophageal cancer	0.000103	0.000278	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CYP1B1—esophageal cancer	0.000103	0.000277	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—HMOX1—esophageal cancer	0.000102	0.000274	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—TYMP—esophageal cancer	9.86e-05	0.000266	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ABCB1—esophageal cancer	9.76e-05	0.000263	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CYP19A1—esophageal cancer	9.65e-05	0.00026	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYP26A1—esophageal cancer	9.59e-05	0.000258	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—HIF1A—esophageal cancer	9.48e-05	0.000255	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ALOX15—esophageal cancer	9.35e-05	0.000252	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—KDR—esophageal cancer	9.07e-05	0.000244	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CREBBP—esophageal cancer	9.02e-05	0.000243	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—TPI1—esophageal cancer	8.92e-05	0.00024	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GSTO1—esophageal cancer	8.92e-05	0.00024	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—HMOX1—esophageal cancer	8.81e-05	0.000237	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	8.64e-05	0.000233	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ALDOB—esophageal cancer	8.55e-05	0.00023	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—NOTCH1—esophageal cancer	8.54e-05	0.00023	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ABCB1—esophageal cancer	8.45e-05	0.000228	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GAPDH—esophageal cancer	8.23e-05	0.000222	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CRABP1—esophageal cancer	8.16e-05	0.00022	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—NOS3—esophageal cancer	8.08e-05	0.000218	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GNG7—esophageal cancer	7.76e-05	0.000209	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CREBBP—esophageal cancer	7.74e-05	0.000209	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—EGFR—esophageal cancer	7.61e-05	0.000205	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PTGS2—esophageal cancer	7.39e-05	0.000199	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—PIK3CA—esophageal cancer	7.27e-05	0.000196	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ALDH2—esophageal cancer	7.27e-05	0.000196	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—NOS3—esophageal cancer	6.93e-05	0.000187	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GSTT1—esophageal cancer	6.92e-05	0.000186	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYP2A6—esophageal cancer	6.84e-05	0.000184	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—PIK3CA—esophageal cancer	6.6e-05	0.000178	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CREBBP—esophageal cancer	6.52e-05	0.000176	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—ERBB2—esophageal cancer	6.49e-05	0.000175	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PTGS1—esophageal cancer	6.48e-05	0.000175	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ENO1—esophageal cancer	6.48e-05	0.000175	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	6.39e-05	0.000172	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PSME2—esophageal cancer	6.39e-05	0.000172	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PSME1—esophageal cancer	6.39e-05	0.000172	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—EP300—esophageal cancer	6.15e-05	0.000166	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—NOS3—esophageal cancer	5.84e-05	0.000157	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CCND1—esophageal cancer	5.73e-05	0.000154	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CREBBP—esophageal cancer	5.65e-05	0.000152	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CDKN1A—esophageal cancer	5.54e-05	0.000149	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYP1B1—esophageal cancer	5.51e-05	0.000148	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PTGS2—esophageal cancer	5.34e-05	0.000144	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—EP300—esophageal cancer	5.27e-05	0.000142	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYP19A1—esophageal cancer	5.18e-05	0.00014	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—NOS3—esophageal cancer	5.06e-05	0.000136	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—HMOX1—esophageal cancer	4.73e-05	0.000127	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PTGS2—esophageal cancer	4.63e-05	0.000125	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MYC—esophageal cancer	4.6e-05	0.000124	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PIK3CA—esophageal cancer	4.55e-05	0.000122	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ABCB1—esophageal cancer	4.54e-05	0.000122	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—EGFR—esophageal cancer	4.5e-05	0.000121	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—EP300—esophageal cancer	4.44e-05	0.00012	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PIK3CA—esophageal cancer	3.9e-05	0.000105	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—EP300—esophageal cancer	3.85e-05	0.000104	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—TP53—esophageal cancer	3.77e-05	0.000102	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PIK3CA—esophageal cancer	3.29e-05	8.85e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CREBBP—esophageal cancer	3.03e-05	8.17e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PIK3CA—esophageal cancer	2.85e-05	7.67e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—NOS3—esophageal cancer	2.72e-05	7.31e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PTGS2—esophageal cancer	2.48e-05	6.69e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—EP300—esophageal cancer	2.07e-05	5.56e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PIK3CA—esophageal cancer	1.53e-05	4.12e-05	CbGpPWpGaD
